1  industry parties interested in personalized respiratory medicine.

2 ction among subjects not taking prescription respiratory medicine.

3 ntary and alternative medicines (14.5 %) and respiratory medicines (0 %).

4  by subject category: all internal medicine, respiratory medicine, and toxicology journals studied ha

5       They were referred from the outpatient respiratory medicine clinic of the hospital.

6 rine, gastroenterological, neurological, and respiratory medicine clinics in secondary care.

7 of an international workshop on personalized respiratory medicine coorganized by the Barcelona Respir

8                             A need exists in respiratory medicine for a technology capable of identif

9 rolled on the trial at the Oxford Centre for Respiratory Medicine (Oxford, UK).

10  access service integrating palliative care, respiratory medicine, physiotherapy, and occupational th

11 nterdisciplinary approach, bringing together respiratory medicine, rehabilitation sciences, social sc

12 nt types from 52 isolates collected from the respiratory medicine unit and elsewhere in Australia.

13  patients with cystic fibrosis attending our respiratory medicine unit have had Scedosporium organism

14 ated from more than one source: one from two respiratory medicine unit inpatients and one from two ep

15    A single common type was isolated from 11 respiratory medicine unit inpatients.

16 f isolates with a single typing pattern from respiratory medicine unit patients may suggest transmiss

17  among active asthmatics taking prescription respiratory medicine, whereas lung function in other act